

BP-50634

Cadonilimab– Anti-PD-1/CTLA4 Bispecific Antibody

Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC).

Product Details	
Species Reactivity	Human
Source	Mammalian Cells
Isotype	Human IgG1 (L234A/L235A) kappa
Class	Anti-Human Bispecific antibodies
Type	Recombinant Humanized
Clone	SP34-2/OKT3
Target	Anti-human PD1/CTLA4
Purity	>99%
Molecular Weight	198.64 kDa
CAS Number	2394841-59-7
Formulation	NA
Storage conditions	Store at -80°C for 2 years. Aliquots should be stored at the same temperature after first use to avoid multiple freeze-thaws.